Wall Street Zen Upgrades Oncocyte (NASDAQ:IMDX) to “Hold”

Oncocyte (NASDAQ:IMDX) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Oncocyte Stock Down 0.5%

IMDX stock opened at $6.04 on Friday. The firm has a market capitalization of $173.11 million, a PE ratio of -2.13 and a beta of 1.33.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.